Comparative analysis of mergers and acquisitions in Indian and international pharmaceutical industry with unique case-lets Online publication date: Tue, 23-Jun-2020
by Som Sekhar Bhattacharyya; Syed Naser
International Journal of Business and Globalisation (IJBG), Vol. 25, No. 1, 2020
Abstract: Mergers and acquisitions (M&A) have become a potent strategy for firms to secure inorganic growth but are also beset with challenges. Pharmaceutical industry has a unique nature due to higher involvement of science in product development and requires firms to develop distinctive and complex capabilities. In this study, the authors undertake a comparative study of different pharmaceutical cases to gather perspectives on M&A practices in Indian and international pharmaceutical industry. Frameworks developed by Bower (2001) and Dyer et al. (2004) are applied to different M&As to understand their applicability and use in Indian and international pharmaceutical contexts. The authors found that Indian firms undertake M&A to reduce R&D investments, to secure strategic resources and to expand product and market reach. Pharmaceutical firms from developed countries mostly acquire firms from developing market for sake of manufacturing knows how and for securing host market.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business and Globalisation (IJBG):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook